Latest News
& Press Releases

Appia Bio’s shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss drugs—and their ultimate place within the anti-obesity medication market.

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges created by the technology.

LB Pharma will test the IPO market to seek funding for a Phase III-ready schizophrenia asset.

The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare disease called Alagille syndrome.

Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights in a move that American Federation of Government Employees national president Everett Kelley called “illegal and immoral.”

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the regulator has reversed course.

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a quarterly basis.

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and losers. Here are five molecules that never made it to the market.

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across clinical trials, we at BioSpace are giving it our best shot.

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” investors, William Blair’s Andy Hsieh predicts weight loss pills will play a bigger role in low- and middle-income countries than in the U.S.

Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed’s B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally Highlights Meuhedet Health Services, Israel’s third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed’s flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel’s four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured lives. The Company is executing a global B2B institutional strategy focused on healthcare organizations, insurers, distributors and government healthcare systems.